Discover All Perspectives.
Published loading...Updated

CStone Presents the Latest Preclinical Findings of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) at 2025 AACR

  • On May 5, 2025, CStone Pharmaceuticals shared findings from early-stage studies of CS2009, a trispecific antibody targeting PD-1, VEGF, and CTLA-4, during the 2025 AACR Annual Meeting held in Suzhou, China.
  • CStone developed CS2009 to combine blockade of PD-1, VEGFA, and CTLA-4, clinically validated immunotherapy targets known for synergistic anti-tumor effects and extended survival benefits.
  • CS2009 enhances efficacy by targeting PD-1/CTLA-4 double-positive T cells and crosslinking VEGFA dimers, showing an up to 300-fold increase in checkpoint inhibitory activity in assays.
  • Preclinical evaluations showed that CS2009 activates T-cells in a dose-dependent manner, has pharmacokinetic characteristics similar to monoclonal antibodies, is very well tolerated, and exhibited no adverse effects at doses up to 100 mg/kg in cynomolgus monkeys.
  • The global phase I trial started in March 2025 in Australia and will expand to China and the US, supporting CS2009's potential as a next-generation immune-oncology backbone against solid tumors including NSCLC.
Insights by Ground AI
Does this summary seem wrong?

70 Articles

All
Left
8
Center
21
Right
4
InsideNoVA.comInsideNoVA.com
+68 Reposted by 68 other sources
Center

CStone Presents the Latest Preclinical Findings of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) at 2025 AACR

SUZHOU, China, May 5, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that a poster presentation of preclinical data of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody), a key asset in CStone Pipeline…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 64% of the sources are Center
64% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ajmc.com broke the news in on Monday, May 5, 2025.
Sources are mostly out of (0)

Similar News Topics